Inhibition of VEGFR-3 by SAR131675 decreases renal inflammation and lymphangiogenesis in the murine lupus nephritis model

Abstract Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune-complex deposits and inflammatory cell infiltrations in multiple organs. Approximately half of lupus patients have nephritis. Lymphangiogenesis is the proliferation of lymphatic vessels (LVs), which r...

Full description

Saved in:
Bibliographic Details
Main Authors: Tian Wang, Wenjia Li, Ji-Hyun Yeom, Zhiheng Liu, Kyoung Min Kim, Kyung Pyo Kang
Format: Article
Language:English
Published: Nature Publishing Group 2025-07-01
Series:Cell Death Discovery
Online Access:https://doi.org/10.1038/s41420-025-02624-4
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849767027654262784
author Tian Wang
Wenjia Li
Ji-Hyun Yeom
Zhiheng Liu
Kyoung Min Kim
Kyung Pyo Kang
author_facet Tian Wang
Wenjia Li
Ji-Hyun Yeom
Zhiheng Liu
Kyoung Min Kim
Kyung Pyo Kang
author_sort Tian Wang
collection DOAJ
description Abstract Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune-complex deposits and inflammatory cell infiltrations in multiple organs. Approximately half of lupus patients have nephritis. Lymphangiogenesis is the proliferation of lymphatic vessels (LVs), which regulate tissue fluid homeostasis and immune cell trafficking, responding to the tissue environment. In this study, we evaluated the therapeutic effect of SAR131675, a selective VEGFR-3 inhibitor, on the murine lupus nephritis model by regulating inflammation and lymphangiogenesis. We evaluated biopsy-proven lupus nephritis with immunohistochemical staining for D2-40, a marker for human lymphatic endothelial cells. For animal experiments, 7- to 8-week-old male BALB/c mice were used. For the induction of a lupus-like model, the dorsal skin of mice was shaved and given topical treatment every other day with 100 μg resiquimod dissolved in 100 μL acetone during the 8-week treatment. We had renal histology and immunofluorescent study for inflammatory cells and lymphatic vessels. We also had a qRT-PCR and Western blot analysis to evaluate inflammatory cytokines and chemokines, lymphangiogenic factors, and TLR7/type I IFN response. A human study found that the higher the revised ISN/RPS LN histopathological classification and modified NIH activity indexes, the more D2-40 (+) lymphatic vessels were expressed in the tubulointerstitial areas. Inhibition of VEGFR-3 by oral SAR131675 treatment decreased the resiquimod-induced glomerular and tubulointerstitial inflammation and attenuated LYVE-1 (+) lymphatic vessel expression in the murine lupus model. Treatment SAR131675 decreased the resiquimod-induced increase of proinflammatory cytokines and chemokines by regulating TLR7/MyD88/IFN-α expression. This study suggests the therapeutic potential of targeting lymphatic proliferation by VEGFR-3 inhibition in lupus nephritis. Modulation of the lymphatic network may provide a novel approach to treating chronic inflammation and attenuating renal autoimmune response.
format Article
id doaj-art-e3ae00ab7b424539ba043d3cce9eb632
institution DOAJ
issn 2058-7716
language English
publishDate 2025-07-01
publisher Nature Publishing Group
record_format Article
series Cell Death Discovery
spelling doaj-art-e3ae00ab7b424539ba043d3cce9eb6322025-08-20T03:04:22ZengNature Publishing GroupCell Death Discovery2058-77162025-07-0111111310.1038/s41420-025-02624-4Inhibition of VEGFR-3 by SAR131675 decreases renal inflammation and lymphangiogenesis in the murine lupus nephritis modelTian Wang0Wenjia Li1Ji-Hyun Yeom2Zhiheng Liu3Kyoung Min Kim4Kyung Pyo Kang5Department of Internal Medicine, Research Institute of Clinical Medicine, Jeonbuk National University Medical SchoolDepartment of Internal Medicine, Research Institute of Clinical Medicine, Jeonbuk National University Medical SchoolDepartment of Internal Medicine, Research Institute of Clinical Medicine, Jeonbuk National University Medical SchoolDepartment of Internal Medicine, Research Institute of Clinical Medicine, Jeonbuk National University Medical SchoolDepartment of Pathology, Jeonbuk National University Medical SchoolDepartment of Internal Medicine, Research Institute of Clinical Medicine, Jeonbuk National University Medical SchoolAbstract Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune-complex deposits and inflammatory cell infiltrations in multiple organs. Approximately half of lupus patients have nephritis. Lymphangiogenesis is the proliferation of lymphatic vessels (LVs), which regulate tissue fluid homeostasis and immune cell trafficking, responding to the tissue environment. In this study, we evaluated the therapeutic effect of SAR131675, a selective VEGFR-3 inhibitor, on the murine lupus nephritis model by regulating inflammation and lymphangiogenesis. We evaluated biopsy-proven lupus nephritis with immunohistochemical staining for D2-40, a marker for human lymphatic endothelial cells. For animal experiments, 7- to 8-week-old male BALB/c mice were used. For the induction of a lupus-like model, the dorsal skin of mice was shaved and given topical treatment every other day with 100 μg resiquimod dissolved in 100 μL acetone during the 8-week treatment. We had renal histology and immunofluorescent study for inflammatory cells and lymphatic vessels. We also had a qRT-PCR and Western blot analysis to evaluate inflammatory cytokines and chemokines, lymphangiogenic factors, and TLR7/type I IFN response. A human study found that the higher the revised ISN/RPS LN histopathological classification and modified NIH activity indexes, the more D2-40 (+) lymphatic vessels were expressed in the tubulointerstitial areas. Inhibition of VEGFR-3 by oral SAR131675 treatment decreased the resiquimod-induced glomerular and tubulointerstitial inflammation and attenuated LYVE-1 (+) lymphatic vessel expression in the murine lupus model. Treatment SAR131675 decreased the resiquimod-induced increase of proinflammatory cytokines and chemokines by regulating TLR7/MyD88/IFN-α expression. This study suggests the therapeutic potential of targeting lymphatic proliferation by VEGFR-3 inhibition in lupus nephritis. Modulation of the lymphatic network may provide a novel approach to treating chronic inflammation and attenuating renal autoimmune response.https://doi.org/10.1038/s41420-025-02624-4
spellingShingle Tian Wang
Wenjia Li
Ji-Hyun Yeom
Zhiheng Liu
Kyoung Min Kim
Kyung Pyo Kang
Inhibition of VEGFR-3 by SAR131675 decreases renal inflammation and lymphangiogenesis in the murine lupus nephritis model
Cell Death Discovery
title Inhibition of VEGFR-3 by SAR131675 decreases renal inflammation and lymphangiogenesis in the murine lupus nephritis model
title_full Inhibition of VEGFR-3 by SAR131675 decreases renal inflammation and lymphangiogenesis in the murine lupus nephritis model
title_fullStr Inhibition of VEGFR-3 by SAR131675 decreases renal inflammation and lymphangiogenesis in the murine lupus nephritis model
title_full_unstemmed Inhibition of VEGFR-3 by SAR131675 decreases renal inflammation and lymphangiogenesis in the murine lupus nephritis model
title_short Inhibition of VEGFR-3 by SAR131675 decreases renal inflammation and lymphangiogenesis in the murine lupus nephritis model
title_sort inhibition of vegfr 3 by sar131675 decreases renal inflammation and lymphangiogenesis in the murine lupus nephritis model
url https://doi.org/10.1038/s41420-025-02624-4
work_keys_str_mv AT tianwang inhibitionofvegfr3bysar131675decreasesrenalinflammationandlymphangiogenesisinthemurinelupusnephritismodel
AT wenjiali inhibitionofvegfr3bysar131675decreasesrenalinflammationandlymphangiogenesisinthemurinelupusnephritismodel
AT jihyunyeom inhibitionofvegfr3bysar131675decreasesrenalinflammationandlymphangiogenesisinthemurinelupusnephritismodel
AT zhihengliu inhibitionofvegfr3bysar131675decreasesrenalinflammationandlymphangiogenesisinthemurinelupusnephritismodel
AT kyoungminkim inhibitionofvegfr3bysar131675decreasesrenalinflammationandlymphangiogenesisinthemurinelupusnephritismodel
AT kyungpyokang inhibitionofvegfr3bysar131675decreasesrenalinflammationandlymphangiogenesisinthemurinelupusnephritismodel